Title : Estrogen receptor beta signaling in CD8+ T cells boosts T cell receptor activation and antitumor immunity through a phosphotyrosine switch.

Pub. Date : 2021 Jan

PMID : 33462142






6 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 Lastly, the ERbeta-selective agonist S-equol was evaluated for its efficacy to boost immune checkpoint blockade (ICB)-based anticancer immunotherapy.Disabling the ERbeta-specific phosphotyrosine switch in tumor-bearing hosts exacerbates tumor growth. Equol estrogen receptor 1 (alpha) Mus musculus
2 Lastly, the ERbeta-selective agonist S-equol was evaluated for its efficacy to boost immune checkpoint blockade (ICB)-based anticancer immunotherapy.Disabling the ERbeta-specific phosphotyrosine switch in tumor-bearing hosts exacerbates tumor growth. Equol estrogen receptor 1 (alpha) Mus musculus
3 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol estrogen receptor 1 (alpha) Mus musculus
4 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol estrogen receptor 1 (alpha) Mus musculus
5 S-equol facilitates TCR activation that stimulates the ERbeta phosphotyrosine switch and boosts anti-PD-1 (Programmed cell death protein 1) ICB immunotherapy.Our mouse genetic study clearly demonstrates a role of the ERbeta phosphotyrosine switch in regulating ERbeta-dependent antitumor immunity in CD8+ T cells. Equol estrogen receptor 1 (alpha) Mus musculus
6 Our findings support the development of ERbeta agonists including S-equol in combination with ICB immunotherapy for cancer treatment. Equol estrogen receptor 1 (alpha) Mus musculus